JPM2018: Nevro Announces FDA Nod For Next-Gen Senza II Device

Redwood City, Calif.-based device-maker Nevro Corp. kicked off the annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 8 with the announcement it received US FDA approval for its next-generation Senza II spinal cord stimulation system and better-than-expected Q4 earnings results.

More from Regulation

More from Policy & Regulation